Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

BioPharma Credit (LSE: BPCR)

Last close As at 21/11/2024

0.96

— 0.00 (0.00%)

Market capitalisation

USD1,258m

Latest Insights

View More

Investment Companies | Review

Biopharma Credit — A quality dividend play with FY22 yield of 12%

Investment Companies | edison tv

BioPharma Credit – executive interview

Investment Companies | Update

Biopharma Credit — New transaction of up to US$50m

Investment Companies | Update

Biopharma Credit — Fully invested after recent transactions
Visit Website

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (0.2) (0.6) (3.4)
Relative (4.2) (9.7) (4.8)
52 week high/low US$1.0/US$0.9

Overview

BioPharma Credit (BPCR) is on track to deliver a strong (possibly record-high) annual NAV total return (TR) in FY22 on the back of a high investment level in H122, rising interest rates benefiting its floating rate loans, as well as healthy prepayment and make-whole fees from the early loan repayments in recent months. This has allowed BPCR to announce a US$0.045 special dividend, which implies a 12.0% dividend yield for FY22 on the current share price. The above-mentioned fees also provide BPCR with a good income runway for the re-deployment of prepayment proceeds. Since being fully invested in August 2018, BPCR achieved a net NAV TR of c 8% per year.

Review

Investment Companies

BioPharma Credit — New debt investment in OptiNose

Review

Investment Companies

BioPharma Credit — Debt and equity investment in BDSI

Review

Investment Companies

Biopharma Credit — Oversubscribed offering fuels further growth

Update

Investment Companies

Biopharma Credit — Leading lender in life sciences